1
|
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MWM. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica 2023; 108:2837-2843. [PMID: 37102614 PMCID: PMC10543165 DOI: 10.3324/haematol.2022.282160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Accepted: 04/14/2023] [Indexed: 04/28/2023] Open
Affiliation(s)
- Johanna Rausch
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Margarita M Dzama
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz
| | - Nadezda Dolgikh
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Hanna L Stiller
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Stephan R Bohl
- Department of Medical Oncology, Dana- Farber Cancer Institute, Boston, MA
| | - Catharina Lahrmann
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Kerstin Kunz
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | | | - Hakim Echchannaoui
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Chun-Wei Chen
- Department of Systems Biology, Beckman Research Institute City of Hope, Duarte, CA
| | - Thomas Kindler
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Konstanze Döhner
- Department of Internal Medicine III, Ulm University Hospital, Ulm
| | | | - Matthias Theobald
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Daniel Sasca
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz
| | - Michael W M Kühn
- Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; German Cancer Consortium (DKTK) partner site Frankfurt/Mainz and German Cancer Research Center (DKFZ) Heidelberg, Germany; University Cancer Center Mainz, Mainz.
| |
Collapse
|
2
|
Potter DS, Du R, Bohl SR, Chow KH, Ligon KL, Bueno R, Letai A. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nat Commun 2023; 14:2897. [PMID: 37210412 DOI: 10.1038/s41467-023-38552-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 05/05/2023] [Indexed: 05/22/2023] Open
Abstract
Malignant pleural mesothelioma (MPM) has relatively ineffective first/second-line therapy for advanced disease and only 18% five-year survival for early disease. Drug-induced mitochondrial priming measured by dynamic BH3 profiling identifies efficacious drugs in multiple disease settings. We use high throughput dynamic BH3 profiling (HTDBP) to identify drug combinations that prime primary MPM cells derived from patient tumors, which also prime patient derived xenograft (PDX) models. A navitoclax (BCL-xL/BCL-2/BCL-w antagonist) and AZD8055 (mTORC1/2 inhibitor) combination demonstrates efficacy in vivo in an MPM PDX model, validating HTDBP as an approach to identify efficacious drug combinations. Mechanistic investigation reveals AZD8055 treatment decreases MCL-1 protein levels, increases BIM protein levels, and increases MPM mitochondrial dependence on BCL-xL, which is exploited by navitoclax. Navitoclax treatment increases dependency on MCL-1 and increases BIM protein levels. These findings demonstrate that HTDBP can be used as a functional precision medicine tool to rationally construct combination drug regimens in MPM and other cancers.
Collapse
Affiliation(s)
- Danielle S Potter
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
- Harvard Medical School, Boston, MA, 02215, USA
| | - Ruochen Du
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
- Harvard Medical School, Boston, MA, 02215, USA
| | - Stephan R Bohl
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
- Harvard Medical School, Boston, MA, 02215, USA
| | - Kin-Hoe Chow
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
- Center for Patient Derived Models, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
| | - Keith L Ligon
- Harvard Medical School, Boston, MA, 02215, USA
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
- Center for Patient Derived Models, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02215, USA
- Cancer Biology Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - Raphael Bueno
- Harvard Medical School, Boston, MA, 02215, USA
- Department of Surgery, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - Anthony Letai
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
- Harvard Medical School, Boston, MA, 02215, USA.
| |
Collapse
|
3
|
Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint A, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell 2020; 38:872-890.e6. [PMID: 33217342 PMCID: PMC7988687 DOI: 10.1016/j.ccell.2020.10.010] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Revised: 08/04/2020] [Accepted: 10/07/2020] [Indexed: 12/20/2022]
Abstract
Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models of acquired resistance to BCL-2 (venetoclax) and MCL-1 (S63845) antagonists, we identify common principles of resistance and persistent vulnerabilities to overcome resistance. BH3 mimetic resistance is characterized by decreased mitochondrial apoptotic priming as measured by BH3 profiling, both in PDX models and human clinical samples, due to alterations in BCL-2 family proteins that vary among cases, but not to acquired mutations in leukemia genes. BCL-2 inhibition drives sequestered pro-apoptotic proteins to MCL-1 and vice versa, explaining why in vivo combinations of BCL-2 and MCL-1 antagonists are more effective when concurrent rather than sequential. Finally, drug-induced mitochondrial priming measured by dynamic BH3 profiling (DBP) identifies drugs that are persistently active in BH3 mimetic-resistant myeloblasts, including FLT-3 inhibitors and SMAC mimetics.
Collapse
Affiliation(s)
- Shruti Bhatt
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA; Department of Pharmacy, National University of Singapore, Singapore
| | - Marissa S Pioso
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Elyse Anne Olesinski
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Binyam Yilma
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Jeremy A Ryan
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Thelma Mashaka
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Buon Leutz
- Department of Bioinformatics and Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Sophia Adamia
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA
| | - Haoling Zhu
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA
| | - Yanan Kuang
- Department of Bioinformatics and Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Abhishek Mogili
- Department of Bioinformatics and Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Abner Louissaint
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA
| | - Stephan R Bohl
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Annette S Kim
- Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA
| | - Anita K Mehta
- Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Sneha Sanghavi
- Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA
| | - Youzhen Wang
- Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA
| | - Erick Morris
- Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA
| | - Ensar Halilovic
- Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA
| | - Cloud P Paweletz
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA
| | - David M Weinstock
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA
| | - Jacqueline S Garcia
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA
| | - Anthony Letai
- Department of Medical Oncology, Dana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
| |
Collapse
|
4
|
Nguyen TM, Scholl K, Idler I, Wais V, Körper S, Lotfi R, Bommer M, Wiesneth M, Schrezenmeier H, Döhner H, Bohl SR, Harsdorf SV, Reinhardt P, Bunjes D, Ringhoffer M, Kuchenbauer F. Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2019; 61:481-484. [DOI: 10.1080/10428194.2019.1660977] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Thanh Mai Nguyen
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Katrina Scholl
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Irina Idler
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Verena Wais
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Sixten Körper
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg- Hessian Ulm, Ulm, Germany
- Institute of Transfusion Medicine, University Hospital of Ulm, Ulm, Germany
| | - Ramin Lotfi
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg- Hessian Ulm, Ulm, Germany
- Institute of Transfusion Medicine, University Hospital of Ulm, Ulm, Germany
| | - Martin Bommer
- Department of Internal Medicine, Alb-Fils Kliniken, Göppingen, Germany
| | - Markus Wiesneth
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg- Hessian Ulm, Ulm, Germany
- Institute of Transfusion Medicine, University Hospital of Ulm, Ulm, Germany
| | - Hubert Schrezenmeier
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg- Hessian Ulm, Ulm, Germany
- Institute of Transfusion Medicine, University Hospital of Ulm, Ulm, Germany
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Stephan R. Bohl
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | | | - Peter Reinhardt
- Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg- Hessian Ulm, Ulm, Germany
- Institute of Transfusion Medicine, University Hospital of Ulm, Ulm, Germany
| | - Donald Bunjes
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Mark Ringhoffer
- Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany
| | - Florian Kuchenbauer
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
- Vancouver General Hospital, L/BMT Program of British Columbia, Vancouver, Canada
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| |
Collapse
|
5
|
Bohl SR, Bullinger L, Rücker FG. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. Int J Mol Sci 2019; 20:E1983. [PMID: 31018543 PMCID: PMC6515298 DOI: 10.3390/ijms20081983] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Revised: 04/17/2019] [Accepted: 04/19/2019] [Indexed: 02/07/2023] Open
Abstract
The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since over the last four decades a stagnation in standard cytotoxic treatment has been observed. But within recent years, remarkable advances in the understanding of the molecular heterogeneity and complexity of this disease have led to the identification of novel therapeutic targets. In the last two years, seven new targeted agents (midostaurin, gilteritinib, enasidenib, ivosidenib, glasdegib, venetoclax and gemtuzumab ozogamicin) have received US Food and Drug Administration (FDA) approval for the treatment of AML. These drugs did not just prove to have a clinical benefit as single agents but have especially improved AML patient outcomes if they are combined with conventional therapy. In this review, we will focus on currently approved and promising upcoming agents and we will discuss controversial aspects and limitations of targeted treatment strategies.
Collapse
Affiliation(s)
- Stephan R Bohl
- Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
| | - Lars Bullinger
- Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine, 13353 Berlin, Germany.
| | - Frank G Rücker
- Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
| |
Collapse
|
6
|
Abstract
INTRODUCTION The majority of patients with acute myeloid leukemia (AML) are older and exhibit a poor prognosis even after intensive therapy. Inducing differentiation and apoptosis of leukemic blasts by DNA-hypomethylating agents, like e.g. azacytidine (AZA) and decitabine (DAC), represent well-tolerated alternative treatment approaches. Both agents show convincing response as single agents in AML. However, there is a lack of knowledge regarding molecular mechanisms and predictive biomarkers for these agents. Areas covered: This review will (i) provide an overview of the current knowledge of molecular mechanisms underlying the action of these drugs, (ii) report promising predictive biomarkers, (iii) elude on new combined treatment options, and (iv) discuss novel approaches to improve outcomes. A literature search was performed using PubMed to find recent major publications, which provide biological and clinical research about epigenetic therapy in AML patients. Expert commentary: Numerous studies have demonstrated that HMA therapy with AZA or DAC may lead to significant response rates, even in pre-treated patients. Nevertheless, there is still an unmet need to further improve outcome in elderly AML patients. Therefore, novel treatment combinations are needed and some of them, such as AZA plus venetoclax, already show promising results.
Collapse
Affiliation(s)
- Stephan R Bohl
- a Department of Internal Medicine III , University Hospital Ulm , Ulm , Germany
| | - Lars Bullinger
- a Department of Internal Medicine III , University Hospital Ulm , Ulm , Germany.,b Department of Hematology, Oncology and Tumorimmunology , Charité University Medicine Berlin , Berlin , Germany
| | - Frank G Rücker
- a Department of Internal Medicine III , University Hospital Ulm , Ulm , Germany
| |
Collapse
|
7
|
Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI, Paschka P, Knudsen S, Döhner K, Döhner H, Claus R, Lübbert M, Bullinger L. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leuk Lymphoma 2017; 58:1-4. [DOI: 10.1080/10428194.2017.1287360] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Stephan R. Bohl
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Anna Dolnik
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Thomas Jensen
- Medical Prognosis Institute (MPI), Hørsholm, Denmark
| | - Katharina M. Lang
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Björn Hackanson
- Department of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany
| | - Verena I. Gaidzik
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Peter Paschka
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Steen Knudsen
- Medical Prognosis Institute (MPI), Hørsholm, Denmark
| | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Rainer Claus
- Department of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany
| | - Michael Lübbert
- Department of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany
| | - Lars Bullinger
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| |
Collapse
|
8
|
Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, Scheffold A, Schneider E, Pochert N, Miller C, Palmqvist L, Staffas A, Mulaw M, Bohl SR, Buske C, Heuser M, Kraus J, O'Neill K, Hansen CL, Petriv OI, Kestler H, Döhner H, Bullinger L, Döhner K, Humphries RK, Rouhi A, Kuchenbauer F. MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J 2016; 6:e508. [PMID: 27935579 PMCID: PMC5223146 DOI: 10.1038/bcj.2016.110] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Affiliation(s)
- K Krowiorz
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - J Ruschmann
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| | - C Lai
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| | - M Ngom
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| | - T Maetzig
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| | - V Martins
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - A Scheffold
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - E Schneider
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - N Pochert
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - C Miller
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - L Palmqvist
- Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.,Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - A Staffas
- Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.,Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - M Mulaw
- Institute of Experimental Cancer Research, Comprehensive Cancer Centre Ulm, Ulm, Germany
| | - S R Bohl
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - C Buske
- Institute of Experimental Cancer Research, Comprehensive Cancer Centre Ulm, Ulm, Germany
| | - M Heuser
- Department of Hematology, Homeostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
| | - J Kraus
- Medical Systems Biology, Ulm University, Ulm, Germany
| | - K O'Neill
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| | - C L Hansen
- Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia, Canada
| | - O I Petriv
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada
| | - H Kestler
- Medical Systems Biology, Ulm University, Ulm, Germany
| | - H Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - L Bullinger
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - K Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - R K Humphries
- Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada
| | - A Rouhi
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - F Kuchenbauer
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| |
Collapse
|
9
|
Bohl SR, Pircher A, Hilbe W. Cancer stem cells: characteristics and their potential role for new therapeutic strategies. ACTA ACUST UNITED AC 2011; 34:269-74. [PMID: 21577035 DOI: 10.1159/000327815] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
With the cancer stem cell (CSC) hypothesis many questions regarding cancer development and drug resistance can be answered more coherently than with the traditional model based on clonal evolution. CSCs are a small subset of cancer cells within the tumour that show stem cell characteristics like self-renewal, the capability to develop into multiple lineages and the potential to proliferate extensively, and are characterised by a typical profile of different markers like CD44 and CD133. In the CSC model, the role of embryonic pathways like Wnt, Hedgehog and Notch is of special interest. This review presents current scientific knowledge on this topic and discusses the potential role of CSC in the resistance against chemotherapy or radiation and presents challenging options for therapeutic interventions.
Collapse
Affiliation(s)
- Stephan R Bohl
- Medical University Innsbruck, Department of Internal Medicine V, Haematology and Oncology, Innsbruck, Austria.
| | | | | |
Collapse
|